Last updated: September 8, 2026
Naphazoline hydrochloride and pheniramine maleate are established over-the-counter ophthalmic ingredients used together for temporary relief of ocular redness and itching caused by allergies. The combination is best known in the United States through Visine-A and equivalent generic products. Its commercial profile is mature, low-cost, and highly competitive. Growth depends more on brand distribution, retail placement, seasonal allergy demand, and product switching than on new clinical development.
The combination has limited standalone financial transparency. Manufacturers do not generally report revenue for naphazoline/pheniramine products separately, and the product is marketed under the FDA over-the-counter monograph framework rather than through a high-value, patent-protected prescription franchise.
What is naphazoline hydrochloride and pheniramine maleate used for?
Naphazoline hydrochloride and pheniramine maleate are ophthalmic active ingredients for temporary relief of eye redness and itching associated with pollen, ragweed, grass, animal dander, and other allergens.
A representative product contains:
| Attribute |
Typical specification |
| Naphazoline hydrochloride |
0.025% |
| Pheniramine maleate |
0.3% |
| Dosage form |
Sterile ophthalmic solution |
| Route |
Topical ocular administration |
| Primary effects |
Redness relief and antihistamine activity |
| U.S. status |
Nonprescription, OTC |
| Leading branded product |
Visine-A Multi-Action Relief |
| Main alternatives |
Ketotifen, olopatadine, artificial tears, generic redness relievers |
Naphazoline is an alpha-adrenergic agonist that constricts conjunctival blood vessels and reduces visible redness. Pheniramine is an H1 antihistamine that reduces allergic itching. The combination addresses two consumer symptoms in one product, which supports its positioning in the seasonal allergy and eye-care categories.
FDA labeling limits use to temporary relief. Consumers are directed to stop use and consult a healthcare professional if pain, vision changes, continued redness or irritation occurs, or symptoms persist beyond the labeled period. Overuse of topical ocular vasoconstrictors can produce rebound redness.
What is the FDA regulatory status of naphazoline and pheniramine eye drops?
The combination is regulated as an OTC ophthalmic product under FDA requirements for active ingredients, labeling, dosage, warnings, and manufacturing quality.
The relevant regulatory framework is the FDA ophthalmic OTC monograph in 21 C.F.R. Part 349. Naphazoline hydrochloride is recognized as an ophthalmic redness-relief active ingredient within the permitted concentration range. Pheniramine maleate is recognized as an ophthalmic antihistamine active ingredient at concentrations used in commercial allergy eye drops.[1][2]
A product marketed under the monograph generally does not require an individual new drug application if it complies with the applicable monograph conditions and other FDA requirements. The regulatory pathway reduces development costs and shortens launch timelines compared with prescription ophthalmic drugs.
What products contain naphazoline hydrochloride and pheniramine maleate?
The principal U.S. branded reference product is Visine-A Multi-Action Relief, marketed by Kenvue following the separation of Kenvue from Johnson & Johnson’s consumer-health business. Equivalent products may be marketed by private-label retailers, generic pharmaceutical companies, and regional consumer-health manufacturers.
The market includes:
- Branded naphazoline/pheniramine eye drops.
- Store-brand versions with the same active ingredients.
- Single-ingredient naphazoline redness relievers.
- Antihistamine-only products containing ketotifen or olopatadine.
- Lubricating drops marketed for dry eye and allergy-associated irritation.
The combination competes partly on convenience and symptom coverage rather than on a differentiated mechanism.
What patents protect naphazoline hydrochloride and pheniramine maleate products?
The active ingredients are old, established compounds, and the core combination does not have a commercially meaningful period of composition-of-matter exclusivity in the United States.
The principal protection profile is:
| Protection category |
Current commercial relevance |
| Active-ingredient patent |
Expired or not commercially relevant |
| Combination patent |
No known blocking patent for the basic OTC combination |
| Formulation patent |
Possible product-specific filings, but no identified industry-wide barrier |
| Method-of-use patent |
No material exclusivity identified for routine allergy-redness relief |
| Orange Book patent listing |
No identified blocking listing for the OTC monograph combination |
| Trademark protection |
Relevant to Visine branding and trade dress |
| Regulatory exclusivity |
No meaningful remaining exclusivity period |
A specific branded formulation could have historical patents covering preservatives, pH control, packaging, delivery systems, or stability. Those rights would not ordinarily prevent competitors from marketing a compliant naphazoline/pheniramine solution under the OTC monograph.
What is the Orange Book status of naphazoline hydrochloride and pheniramine maleate?
The combination is not generally treated as a conventional Orange Book-protected prescription product. OTC monograph products are not comparable to prescription NDAs with a large Orange Book patent estate.
The practical result is that the main branded product does not appear to have a listed patent barrier that would prevent competing OTC products. Patent expiration dates for the core combination are therefore not a material determinant of generic entry.
When does naphazoline and pheniramine lose exclusivity?
The product has effectively operated in a post-exclusivity market for many years. There is no relevant future cliff comparable to the loss of patent protection for a blockbuster prescription drug.
Commercial exclusivity has already been eroded through:
- Expired historical patents covering the ingredients and basic product concepts.
- OTC monograph availability.
- Retailer private-label competition.
- Consumer substitution among allergy and redness-relief products.
- Low formulation complexity.
The remaining defensible assets are brand recognition, retail distribution, packaging, consumer trust, quality systems, and advertising. These assets can support price premiums but do not prevent substitution.
Are there Paragraph IV challenges to naphazoline and pheniramine products?
No material Paragraph IV litigation is associated with the basic naphazoline hydrochloride/pheniramine maleate OTC combination.
Paragraph IV certifications apply primarily to ANDAs referencing listed prescription drugs with Orange Book patents. A monograph-based OTC product does not create the same litigation pathway. Competitors can generally enter by complying with the applicable FDA monograph, labeling requirements, facility standards, and marketing rules.
This substantially reduces litigation risk compared with prescription ophthalmic drugs such as branded antihistamine or anti-inflammatory products protected by listed patents.
What formulations are protected by naphazoline and pheniramine patents?
No formulation category has been identified as a broad market barrier for this combination. Commercial formulations generally use conventional sterile ophthalmic-solution technology.
Relevant formulation variables include:
- Preservative selection.
- Buffer system and pH.
- Isotonicity.
- Drop size and delivery accuracy.
- Container-closure integrity.
- Multidose bottle stability.
- Compatibility with plastic packaging.
- Sterility and preservative effectiveness.
These factors create manufacturing and quality-control requirements, but they are not equivalent to durable patent exclusivity. A competitor with established ophthalmic manufacturing capability can reproduce the product profile without developing a novel clinical mechanism.
Single-dose preservative-free delivery, specialized dispensing systems, or improved tolerability could create differentiated products. Those products would compete on consumer preference and product claims, not necessarily on the basic naphazoline/pheniramine combination.
How strong is the patent estate for naphazoline hydrochloride and pheniramine maleate?
The patent estate is weak as a barrier to entry and has little value as a licensing or litigation asset.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Exhausted |
| Basic combination protection |
Weak or absent |
| Formulation protection |
Narrow and product-specific |
| Manufacturing protection |
Limited to particular processes or devices |
| Method-of-use protection |
Minimal for ordinary OTC allergy use |
| Regulatory exclusivity |
None of material commercial value |
| Trademark value |
Stronger than patent value for leading brands |
| Generic-entry exposure |
High |
A company considering acquisition or licensing would value the brand, retailer access, manufacturing reliability, and consumer repeat purchase more than the patent portfolio.
What patent litigation affects naphazoline and pheniramine products?
No major current patent litigation is known to affect the basic U.S. OTC combination. The absence of listed-patent litigation lowers legal costs and reduces the likelihood of a delayed generic or private-label launch.
Potential disputes are more likely to involve:
- Trademark infringement.
- Trade dress.
- Advertising claims.
- Product liability.
- Manufacturing quality.
- Sterility failures.
- Labeling compliance.
- Retail exclusivity arrangements.
These disputes can affect commercial performance but do not create the same binary launch risk as prescription patent litigation.
Which companies are challenging the branded market?
Competition comes from generic and private-label manufacturers rather than from a single named Paragraph IV challenger. Retailers can source equivalent products from contract manufacturers and use store brands to compete with Visine.
The competitive field includes:
- Kenvue and the Visine brand.
- Generic ophthalmic manufacturers.
- Retail pharmacy private-label suppliers.
- Manufacturers of ketotifen and olopatadine drops.
- Producers of artificial tears and lubricant products.
- Prescription and OTC allergy-eye-care brands.
Ketotifen and olopatadine are important substitutes because they provide antihistamine and mast-cell-stabilizing activity without relying on a topical vasoconstrictor. Their positioning can appeal to consumers seeking allergy treatment rather than immediate cosmetic redness reduction.
What is the market and financial trajectory for the combination?
The financial trajectory is mature and defensive rather than high growth. Revenue is driven by recurring seasonal demand, household penetration, retail availability, and brand pricing.
Public companies generally report Visine and similar products within broader consumer-health or eye-care categories. Product-specific sales, operating margins, and unit volumes are not normally disclosed in annual reports. Kenvue reports at segment and category levels rather than publishing a separate financial statement for Visine-A.[3]
Revenue drivers
The main revenue drivers are:
- Spring and summer pollen seasons.
- Consumer awareness of ocular allergy symptoms.
- Pharmacy and mass-retail shelf placement.
- Digital commerce and search visibility.
- Brand trust and repeat purchase.
- Multi-pack and travel-size formats.
- Retailer promotion and coupons.
Revenue constraints
The principal constraints are:
- Low switching costs.
- Store-brand substitution.
- Discounting.
- Mature category penetration.
- Competition from antihistamine-only products.
- Consumer concern about rebound redness.
- Limited ability to raise price without volume erosion.
The product can maintain nominal sales through pricing and distribution even when unit volume is flat. Inflation-adjusted growth is more difficult because the formulation has limited clinical differentiation.
Financial trajectory by period
| Period |
Expected commercial pattern |
| Historical |
Brand-led category creation and broad OTC distribution |
| Current |
Mature demand with generic and private-label pressure |
| Near term |
Stable to low growth, dependent on allergy seasons and pricing |
| Medium term |
Margin pressure from retailer brands and substitution |
| Long term |
Continued niche demand, but limited innovation-driven expansion |
No reliable public basis supports assigning a standalone annual revenue figure to naphazoline/pheniramine products. Reported company-level consumer-health revenue should not be attributed to this combination without product-level disclosure.
What generic entry risks exist?
Generic and private-label entry risk is high because the product is simple, familiar, and regulated under an OTC monograph.
A competitor must still meet meaningful technical requirements:
- Sterile ophthalmic manufacturing.
- Validated filling and packaging processes.
- Stability data.
- Preservative and microbiological controls.
- Accurate active-ingredient assay.
- Compliant Drug Facts labeling.
- Appropriate quality-system controls.
- Reliable retail supply.
These requirements create operational barriers, but they are manageable for established ophthalmic manufacturers. They do not create a strong barrier for the broader pharmaceutical industry.
The most likely generic-launch scenario is incremental private-label expansion rather than a single large launch event. Retailers can add equivalent products as part of their allergy and eye-care assortment, with pricing below the branded product.
How does naphazoline/pheniramine compare with competing eye-allergy drugs?
| Product type |
Main benefit |
Patent position |
Commercial risk to combination |
| Naphazoline/pheniramine |
Redness and itching relief |
Mature OTC |
Baseline product |
| Ketotifen |
Antihistamine and mast-cell stabilization |
OTC generic competition |
High substitution risk |
| Olopatadine |
Allergy relief with branded and generic products |
Reduced after generic entry |
High substitution risk |
| Artificial tears |
Lubrication and dilution of allergens |
Minimal patent barrier |
Moderate substitution risk |
| Prescription agents |
Targeted treatment for more severe disease |
Product-specific |
Limited direct overlap |
The combination remains competitive when consumers prioritize rapid redness reduction and a low retail price. It is less advantaged when consumers prioritize longer-duration allergy control or wish to avoid vasoconstrictors.
What manufacturing and geographic IP barriers apply?
Geographic barriers are limited. The active ingredients and basic product concept are widely known, and the principal U.S. pathway is based on OTC monograph compliance.
Commercial barriers differ by region because countries apply different rules for OTC status, pharmacy distribution, product claims, preservatives, and importation. A company expanding internationally must address:
- Local product registration.
- Pharmacopoeial standards.
- Sterility requirements.
- Label translation.
- Advertising restrictions.
- Permitted active-ingredient concentrations.
- Pharmacovigilance and complaint handling.
- Local supply and distribution.
Manufacturing scale, quality assurance, and retailer access are more important than geographic patent rights.
What licensing deals involve naphazoline hydrochloride and pheniramine maleate?
No material recent licensing transaction has been publicly associated with the basic combination. Licensing value is more likely to arise from:
- A recognized consumer brand.
- Retail distribution rights.
- A preservative-free delivery system.
- A novel multidose container.
- Manufacturing capacity.
- Regional commercialization rights.
- A broader ophthalmic portfolio.
A license limited to the active ingredients would have low strategic value because the ingredients are widely available and the regulatory pathway is established.
Key Takeaways
- Naphazoline hydrochloride and pheniramine maleate are mature OTC ophthalmic ingredients used for temporary relief of eye redness and allergy-related itching.
- Visine-A is the leading branded reference product in the U.S. market.
- The combination is marketed under the FDA OTC ophthalmic monograph framework.
- No material Orange Book patent barrier or Paragraph IV challenge is associated with the basic combination.
- Patent strength is low; brand, distribution, quality, and retail execution are the primary commercial assets.
- Generic and private-label entry risk is high.
- Standalone product revenue is not publicly disclosed by major manufacturers.
- Near-term financial performance is likely to be stable or low growth, with seasonal demand and pricing offsetting unit-volume pressure.
- Ketotifen, olopatadine, artificial tears, and other eye-care products create substantial substitution risk.
- Manufacturing quality and sterile ophthalmic capability matter operationally, but they do not create durable market exclusivity.
FAQs
Is naphazoline hydrochloride and pheniramine maleate the same as Visine-A?
Visine-A is a branded product containing these active ingredients at commonly marketed ophthalmic concentrations. Other manufacturers may sell equivalent products with the same active ingredients.
Can a company launch a generic naphazoline/pheniramine eye drop without challenging a patent?
Generally, yes, if the product complies with the applicable FDA OTC monograph and other requirements. A Paragraph IV patent challenge is not normally required for a monograph-based product without a blocking Orange Book patent.
Does naphazoline/pheniramine have biosimilar competition?
No. The product is a small-molecule ophthalmic drug, not a biologic. Biosimilar rules do not apply. Competition comes from generics, private-label products, and therapeutically substitutable eye drops.
What is the main commercial advantage of the combination?
Its main advantage is dual symptom coverage: naphazoline reduces visible redness, while pheniramine relieves allergy-related itching. The product also benefits from brand familiarity and broad retail distribution.
Is the combination attractive for pharmaceutical licensing?
The active-ingredient combination alone has limited licensing value. A transaction would be more commercially defensible if it included a recognized brand, retail access, proprietary delivery technology, sterile manufacturing capacity, or rights to a broader ophthalmic portfolio.
References
-
U.S. Food and Drug Administration. (2024). Over-the-counter monograph M012: Ophthalmic drug products for over-the-counter human use. FDA.
-
Code of Federal Regulations. (2024). 21 C.F.R. Part 349: Ophthalmic drug products for over-the-counter human use. U.S. Government Publishing Office.
-
Kenvue Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
DailyMed. (2024). Visine-A multi-action relief ophthalmic solution labeling. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Drug products marketed without an approved new drug application under the OTC monograph system. FDA.
